Sunday, 23 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com

VISTIN PHARMA Stock Went Up By Over 12% At Session Start On Friday

Loading stream...

(VIANEWS) - Shares of VISTIN PHARMA (Oslo Børs All-share Index_GI: VISTN.OL) jumped by a staggering 12.91% to kr18.80 at 10:41 EST on Friday, following the last session's upward trend. Oslo Børs All-share Index_GI is sliding 0.78% to kr1,405.92, after five consecutive sessions in a row of losses. This seems, as yet, a somewhat down trend trading session today.

About VISTIN PHARMA

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin hydrochloride APIs and direct compressive granulates for the pharmaceutical industry. The company was incorporated in 2015 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.96.

PE Ratio

VISTIN PHARMA has a trailing twelve months price to earnings ratio of 19.58. Meaning, the purchaser of the share is investing kr19.58 for every norwegian krone of annual earnings.

Volume

Today's last reported volume for VISTIN PHARMA is 58691 which is 298.95% above its average volume of 14711.

Volatility

VISTIN PHARMA's last week, last month's, and last quarter's current intraday variation average was a negative 0.61%, a negative 0.13%, and a positive 2.18%.

VISTIN PHARMA's highest amplitude of average volatility was 2.76% (last week), 1.15% (last month), and 2.18% (last quarter).

More news about VISTIN PHARMA (VISTN.OL).